Physician profile
Ravi C Shah
NPI 1013999895
$1,295,184.98
in general payments reported to CMS, 2019-2025
89 companies · $222K in 2025
The $222K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130K · 2020: $184K · 2021: $271K · 2022: $170K · 2023: $165K · 2024: $153K · 2025: $222K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $368K · Consulting Fee: $88K · Travel and Lodging: $32K · Honoraria: $29K · Food and Beverage: $23K · Education: $16.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $368,060.00 |
| Consulting Fee | $87,983.67 |
| Travel and Lodging | $31,715.60 |
| Honoraria | $29,327.00 |
| Food and Beverage | $22,729.86 |
| Education | $16.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $581,292.75 | 2019-2025 | Botox, Ubrelvy, Qulipta |
| Allergan, INC. | $379,307.87 | 2019-2022 | |
| Amgen INC. | $92,716.93 | 2019-2023 | Aimovig |
| Biohaven Pharmaceuticals, INC. | $72,725.25 | 2020-2021 | |
| Pfizer INC. | $38,538.23 | 2019-2025 | |
| Axsome Therapeutics, INC. | $33,701.10 | 2025 | Symbravo |
| Impel Pharmaceuticals INC. | $32,442.44 | 2022-2023 | Trudhesa |
| Teva Pharmaceuticals USA, INC. | $17,420.62 | 2019-2025 | Ajovy, Austedo Xr |
| Biohaven Pharmaceutical Holding Company Ltd. | $16,274.37 | 2022 | |
| Lundbeck LLC | $13,179.64 | 2019-2025 | Vyepti, Rexulti |
| Promius Pharma LLC | $1,474.33 | 2019 | |
| Neurocrine Biosciences, INC. | $1,251.31 | 2019-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $962.63 | 2019-2025 | Rystiggo, Fintepla, Zilbrysq |
| Biogen, INC. | $915.63 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Avanir Pharmaceuticals, INC. | $880.23 | 2019-2021 |
Show all 89 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.